Fine-needle aspiration (FNA) of the thyroid gland is a widely accepted and accurate method for triaging patients with thyroid nodules. Thyroid FNA suffers from a reporting confusion due to multiplicity of category terminologies. To address this, The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) was recently introduced for unifying the terminology and morphologic criteria along with the corresponding risk of malignancy.
Introduction
Fine-needle aspiration (FNA) of the thyroid gland has proven to be an important and widely accepted, cost-effective, simple, safe, and accurate method for triaging patients with thyroid nodules. (1) By using FNA of the thyroid, 70-80% of thyroid lesions can be classified as benign or malignant with 92% negative predictive value for a benign diagnosis and 100% positive predictive value for malignancy. (2) It has an essential role in the evaluation of euthyroid patients with a thyroid nodule as it reduces the rate of unnecessary thyroid surgery for patients with benign nodules and appropriately triages patients with thyroid cancer to appropriate surgery. (3) Literature is deficient on the exact frequency of thyroid nodules and the associated rate of malignancy in Saudi population. Nonetheless, nodular thyroid diseases are common especially in mountainous areas of the western region of Saudi Arabia (4) and thyroid cancer is the second most common cancer among females accounting for 424 (10.2%) among 4156 total cancers recorded in Saudi females during 2006. (5) In the United States, 4 to 7 percent of the adult population has a palpable thyroid nodule. (6) However, only 1 of 20 clinically identified nodules are malignant. (6) This corresponds to approximately 2 to 4 per 100,000 people per year, constituting only 1 percent of all cancers and 0.5 percent of all cancer deaths. (6) It is estimated that up to 30 million patients in the United States have thyroid nodules larger than 1 cm. In comparison with the high prevalence of thyroid nodules, 30,000 patients are diagnosed with thyroid malignances each year. (6, 7) Given the high prevalence of nodules combined with the impracticality of surgically excising all nodules, FNA plays a vital role as a screening test. (2) Every patient with a palpable or incidental thyroid nodule is a candidate for FNA. A nodule that appears either iso-or hypo-functioning on radionuclide scan should be considered for FNA based on the US (ultrasound) findings. (6, 8) Incidental lesions detected by US have a cancer risk of approximately 10-15% and should undergo dedicated thyroid sonographic evaluation. (9) A nodule of any size with sonographically suspicious features should also be considered for FNA. (10, 11) However, despite its widespread use, thyroid FNA currently suffers from a reporting confusion: multiplicity of category names, descriptive reports without categories and variable surgical pathology terminology. (10) Lack of consistency in reporting thyroid FNA has led to wide variances in sensitivity and specificity calculations depending on what one considers to be true and false positives/negatives and resulted in confusion among clinicians on how to manage patients who do not have a clear-cut negative or positive thyroid FNA result. (12) This confusion in diagnostic terminology and clinician perception of its inconsistency was addressed in 2007 by the National Cancer Institute (NCI) Thyroid FNA of the Science Conference wherein the terminology and morphologic criteria for reporting thyroid FNA were concluded thus forming the framework for The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC). (6, 13, 14) The System improves the clarity of communication among cytopathologists and other health care providers, predicts the cancer risk and reduces unnecessary surgery for patients with benign nodules and appropriately triages patients with malignant nodules for timely clinical intervention. (14, 15) It allows easy and reliable sharing of data from different laboratories for national and international collaboration and comparison by establishing a common language. (14, 15) There have been few studies validating the utility and diagnostic accuracy of FNA thyroid across different regions of Saudi Arabia, (5, (16) (17) (18) (19) to the knowledge of authors there are none reporting feedback on the application of the recently established system of TBSRTC within the context of the risk of thyroid malignancies among Saudi population. However several international studies and reviews have been published in this regard. (6, 13, 15, (20) (21) (22) (23) (24) (25) (26) (27) This study was performed to study the diagnostic utility of TBSRTC for reporting the rate of thyroid malignancies.
Objective
To study retrospectively the diagnostic utility of TBSRTC at our institution and report the malignancy risk for FNA of thyroid lesions among Saudi patients and compare it with previous studies.
Materials and Methods
A retrospective study including all FNAs of the thyroid lesions between Jan 2005-Dec 2010 was performed. The study identified 1050 FNA procedures performed at KAUH of which 562 were thyroid FNAs. 250 belonged to Saudi patients. All cytology specimen data of these cases was collected through a computerized search of the Cytopathology archives at KAUH (King Abdulaziz University Hospital), Jeddah, KSA. The data was filtered using appropriate SNOWMED (Systematized Nomenclature of Human Medicine) morphology codes indicating the following parameters: Date of FNA, Personal Identity (Medical Record number, Age, Sex, Nationality etc.), Clinical and radiological diagnosis, Morphology, and Topography.
The data was rechecked manually to delete duplications. Computerized search was then exported to Microsoft Excel format and used for analysis. Specific target group was identified. Interpretations were recorded by three cytopathologists as per the existing international standards. Manual review of cytology reports was then completed twice independently and discrepancy, if any, was resolved through a repeat review. Most of the thyroid FNAs performed at KAAUH use the conventional Papanicolaou and Diff Quick stained smears. Occasionally Thin prep slides are used. Thyroid lesions were classified according to the TBSRTC 6-tier diagnostic categories as in Table 1 (6, 13) also published in form of an atlas (14) into; a) Non diagnostic ND/unsatisfactory UNS;
Smears were considered as nondiagnostic when a thyroid FNA sample failed to fulfill the recommended criteria for adequacy which are presence of a minimum of six groups of well-visualized (i.e., well-stained, undistorted, and unobstructed) follicular cells, with at least ten cells per group, preferably on a single slide, absence of colloid or only blood. (28) Aspirates diagnosed as cystic fluid were recorded as such but considered as nondiagnostic. In calculating the malignancy follow-up rate for the benign category, the total number of benign FNA diagnoses was used as the denominator, as similarly performed in other studies. (15, 20, 29) For all other diagnostic categories, malignancy follow-up rates were calculated by using the number of cases with follow-up histology results. If a patient had multiple FNA samples in the same procedure yielding two different diagnoses, only the diagnosis with higher malignant potential was used for calculating malignancy follow-up rates (for example if a single FNA had a diagnosis of "hyperplastic nodule" and "suspicious for medullary carcinoma" on two separate passes, the case was included in the calculation for the SM follow-up rate and not for the benign group). belonged to Saudi patients. The overall distribution of diagnoses of thyroid FNAs in Saudi patients using TBSRTC are presented in Table 2 . Among the 250 thyroid FNAs in Saudis, 84 were followed by surgical resection (partial or total thyroidectomy).There were 20 cases of malignancy, 63 benign and 1 remained as AUS on resection, giving an overall surgical yield of malignancy of 23.8%. Table 3 presents the total number and the overall distribution of benign and malignant cases on surgical resection. Table 4 presents the rate of malignancy on surgical resection for FNA thyroid diagnostic categories using TBSRTC. Tables 5 and 6 we present the analytical comparison of the percentage distribution of FNA thyroid diagnostic categories and follow up malignancy rate of our study using TBSRTC with 3 other published studies. [20] 2011 % no space
Jo VY et al [15] 2010 % Lee K et al [21] [20] 2011 % (n=221) Jo VY et al [15] 2010 % (n=892) Lee K et al [21] 
Discussion
We found that classification of thyroid lesions according to TBSRTC standardized nomenclature yields similar results for risk of malignancy as reported by others using the same system. Lee K et al (21) performed a similar retrospective study using TBSRTC on 4966 thyroid aspirates and reported malignancy rates as follows: ND, 4.2%; BN, 0%; AUS/AFLUS ,41.2%; SFN, 46.4%; SM, 48.4%; and MGT, 78.4%. Jo VY et al [15] reported the following malignancy rates using TBSRTC on 3080 thyroid aspirates: ND, 8.9; BN, 1.1%; AUS/AFLUS, 17%; SFN, 25.4%; SM, 70%; and MGT, 98.1%. Her-Juing Wu H et al [20] reported their institutional experience using TBSRTC on 1382 thyroid aspirates with a malignancy rates using the same calculations as follows: BN, 3%; AUS/AFLUS, 6%; SFN, 22%; SM, 56%; and MGT, 100%.
The rate of malignancy in the present study was comparable in most of the categories to that mentioned in TBSRTC (14) and other published studies, (15, 20, 21) except the ND/UNS and AUS. The ND/UNS category in our study yielded a malignancy rate of 20% with 1 case turning out to be malignant among 5 follow up resections. A thyroid FNA sample is considered adequate for evaluation if it contains a minimum of six groups of wellvisualized (i.e., well-stained, undistorted, and unobstructed) follicular cells, with at least ten cells per group, preferably on a single slide. (28) The use of these well-defined criteria for adequacy is helpful because they improve the diagnostic efficiency of thyroid FNA and avoid unnecessary surgery for benign non neoplastic thyroid lesions. (30) The most common pitfalls for false-negative diagnoses in FNA thyroid aspirates reported by Bakhos et al consisted of suboptimal material and under diagnosis of papillary carcinoma due to cystic degeneration with a false-negative rate of 4%. (31, 32) Raab et al (33) have also emphasized that suboptimal specimens can be a significant source of false negatives in thyroid cytology. Cystic lesions with a non-diagnostic aspirate should undergo repeat FNA.
(34) In our study the case which turned out to be malignant in ND/UNS category was papillary carcinoma with solid and insular pattern. Lesional characteristics other than cystic features which cause sampling error are thyroid glands with multiple nodules, calcification and fibrosis.
(35) Sample adequacy of FNA thyroid may be affected by the accuracy of lesion and needle localization 'geographic miss of the needle', the method of guidance, the number of aspirated samples, the needle gauge, the aspiration technique, and the presence or absence of on-site facilities for immediate cytologic examination. (36) ND/UNS cytologic findings may also result from poor fixation, preparation, or staining or from excessive blood, necrotic material, or debris obscuring cellular details, misinterpretations. (29, 37) It is, however, important to keep in mind that ND/UNS specimen does not mean negative specimen.
In the AUS category the malignancy rate in the present study is 50% as opposed to 5-15% mentioned in TBSRTC (28) and upto 41.2% (21) as in other studies ( Table 6 ). The less number of cases diagnosed as AUS in the present study could be explained by the strict adherence to diagnostic criteria and the cytopathologist's efforts in our practice setting to avoid ambiguity and keep the use of AUS to a minimum. The frequency of AUS interpretations should be in the range of approximately 7% of all thyroid FNA interpretations. This figure may be further refined as more laboratories report their experiences using the AUS designation within the context of these criteria. AUS is a category of last resort and should not be used indiscriminately. (38) The case diagnosed as AUS on cytology was sparsely cellular and showed monomorphic population of small non cohesive cells (resembling follicular) with high nuclear cytoplasmic ratio (no colloid) which probably explains why it turned out to be medullary carcinoma on histology.AUS is a heterogeneous category, which reflects the difficulty in the cytological diagnosis of the follicular lesions of thyroid. (10) It includes cases in which the cytomorphological findings are not representative of a benign lesion yet the degree of cellular or architectural atypia is not sufficient to render an interpretation of follicular neoplasm⁄suspicious for a follicular neoplasm or suspicious for malignancy. (10) This diagnosis may also be used in thyroid FNA specimens that are less than optimal due to limited cellularity, poor fixation and obscuring blood. This group can benefit from repeat FNA and correlation with clinical and radiological findings. (10) However, because the category is heterogeneous and somewhat subjective, there exist and will likely remain differences between observers in using this diagnosis. (39) The use of this category by different pathologists will vary, and AUS can be expected to have, at best, only fair reproducibility. (38) In the hands of an experienced cytopathologist, accurate localization of the lesion either by palpation or by ultrasound, performing between 1-5 aspirates for thyroid nodules of 1-2 cms size with 20-27 gauge needles, using standard sampling technique, supported by immediate on-site cytological analysis can ensure specimen adequacy. (36, 37, 40) Nodules with an initial ND/UNS result should be re-aspirated, but no sooner than 3 months later; the 3-month interval is recommended to prevent false positive interpretations due to reactive/reparative changes. (11) Circumstances that require repeat FNA include sample inadequacy, nodule enlargement, cyst recurrence, or clinical or imaging findings that arouse suspicion about the presence of a malignancy even when cytological findings in the biopsy specimen indicate benignity. (36, 41) Ultrasound guidance with immediate, on-site adequacy evaluation is preferred for repeat aspiration after an initial ND/UNS specimen, especially for solid nodules. Repeating the FNA results in a diagnostic interpretation in up to 60% of cases, (42) in several studies US guided FNAs have shown to reduce the rates of non-diagnostic (i.e., insufficient cells and/or colloid) and falsenegative aspirates. (43) Given that the diagnostic category of AUS is associated with low specificity and positive predictive value, the appropriate follow-up is controversial. Some authorities recommend repeat FNA, repeat ultrasound scans, or radio-nucleotide uptake studies. (36) Reports have even suggested the use of liquid-based cytology and immunocytochemistry to improve diagnostic accuracy. Radiological correlation may be helpful in improving the positive predictive value of the "AUS" category. Besides increasing size, ultrasonographic features such as hyperechogenicity, irregular nodule borders, calcifications and abnormalities of vasculature all favour a malignancy. (39) FNA of the thyroid can be used as either a screening test for follicular carcinoma, or as a diagnostic test for other thyroid carcinomas including papillary carcinoma, medullary carcinoma, undifferentiated carcinoma, and lymphoma.
(40) Diagnostic limitations inherent to thyroid FNAs underscores the importance of clinical correlation in the management of patients with thyroid nodules Jo VY et al. (15) However, the main purpose of the FNA is to determine the correct surgical procedure when surgery is needed.
(44) This allows appropriate triage to FNA versus surgery based on the significant difference in the risk of subsequent malignancy in all the categories. Implementation of TBSRTC appears to improve the quality of reporting by lowering the number of ambiguous and implicit diagnoses and decreases the overall surgery rates, particularly for benign lesions. Our results were reproduced from retrospective classification, which is a limitation to our study. We did not review all the FNA cases; apart from cases in the gray zone .We used the "most matching criteria" while classifying the lesions. This process relied on the original interpretation (given by 3 cytopathologists at the KAAU Hospital, Jeddah, Saudi Arabia in the period studied) and our review of the original diagnosis report .Most cytopathologists are aware, there can be wide range of interobserver variability in diagnostic thresholds and varied terminologies used by pathologists within the same department (45) which added to the limitations of the study.
In conclusion; at the KAAUH of Jeddah, Saudi Arabia, retrospective classification of FNAs of thyroid lesions among Saudi patients using TBSRTC yields similar results for rate of malignancy as reported by others. However the malignancy rates found for ND/UNS (20%) raise the possibility of malignancy risk in this category and validate the past observations that sample inadequacy is a common cause of false negative thyroid FNAs with a reported false negative rate of up to 25% in literature. (33) It is pertinent to mention here that no risk is reported for this category in the TBSRTC. Our malignancy rate for AUS (50%), underscores the importance of using this terminology carefully and sparingly and that if applied strictly its subsequent malignancy rate may not be always low as reported in TBSRTC. (38) Prospective studies using the TBSRTC will lend further insight into our results and the usefulness of TBSRTC.
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